Skip to Content

Benefit-Risk Assessment in Pharmaceutical Research and Development

Edited by Andreas Sashegyi, James Felli, Rebecca Noel

To Be Published November 26th 2013 by Chapman and Hall/CRC – 224 pages

Series: Chapman & Hall/CRC Biostatistics Series

Purchasing Options:

  • Hardback: $89.95
    978-1-43-986794-5
    Not yet available

Description

This work presents an overview of benefit-risk assessment approaches for pharmaceutical research and development. It covers various decision-making points along the R&D spectrum that would benefit from benefit risk analysis, including during lead development and optimization, early and late planning of clinical development, and regulatory review. The book also looks at health outcomes and comparative effectiveness analysis. In addition, the authors address current and future barriers to using risk-benefit modeling, including greater regulatory acceptance.

Name: Benefit-Risk Assessment in Pharmaceutical Research and Development (Hardback) – Chapman and Hall/CRC 
Description: Edited by Andreas Sashegyi, James Felli, Rebecca Noel. This work presents an overview of benefit-risk assessment approaches for pharmaceutical research and development. It covers various decision-making points along the R&D spectrum that would benefit from benefit risk analysis, including during lead...
Categories: Statistics for the Biological Sciences, Clinical Implementation, Drug Design & Development